Current status of NMDA antagonist interventions in the treatment of nonketotic hyperglycinemia

Clinical Neuropharmacology

Volumn 21, Issue 2, 1998, Pages 71-79

  Deutsch, Stephen I ^a,b   Rosse, Richard B ^a,b   Mastropaolo, John ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

NMDA receptor complex; Nonketotic hyperglycinemia

Indexed keywords

ARGININE; BENZOIC ACID; BETAINE; CARNITINE; CHOLINE; DEXTROMETHORPHAN; DIAZEPAM; FOLINIC ACID; GLYCINE; KETAMINE; MAGNESIUM ION; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENOBARBITAL; STRYCHNINE; TRYPTOPHAN;

AGITATION; AMINO ACID BLOOD LEVEL; ANOREXIA; CLINICAL ARTICLE; DOSE RESPONSE; FEMALE; GASTRITIS; HUMAN; HYPERGLYCINEMIA; INFANT; INTRAGASTRIC DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SEDATION; SEIZURE; SOMNOLENCE; VOMITING;

ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE; HUMANS; HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA; KETAMINE; METABOLIC DISEASES; N-METHYLASPARTATE; TRYPTOPHAN;

EID: 0031925273     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Deutsch SI, Deutsch LH, Weizman R. Nonketotic hyperglycinemia: a paradigm for the application of neuroscicnce to the understanding and treatment of a developmental disorder. In: Deutsch SI, Weizman A, Weizman R, eds. Application of basic neuroscience to child psychiatry. New York: Plenum Publishing, 1990:165-80.
2. McDonald JW, Johnston MV. Nonketotic hyperglycinemia: pathophysiological role of NMDA-type excitatory amino acid receptors. Ann Neurol 1990;27:449-450.
3. Tada K, Kure S. Non-ketotic hyperglycinemia: molecular lesion, diagnosis and pathophysiology. J Inherit Metab Dis 1993;16:691-703.
4. Hamosh A, McDonald JW, Valle D, Francomano CA, Niedermeyer E, Johnston MV. Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant, J Pediatr 1992; 121:131-5.
5. Schmitt B, Steinmann B, Gitzelmann R, Thun-Hohenstein L, Mascher H, Dumermuth G. Nonketotic hyperglycinemia: clinical and electrophysiologic effects of dextromethorphan, an antagonist of the NMDA receptor. Neurology 1993;43:421-4.
6. Schmitt B, Steinmann B. Dextromethorphan in infantile nonketotic hyperglycinemia. J Pediatr 1993;122:324-5.
7. Hamosh A, Valle D, Johnston MV. Dextromethorphan in infantile nonketotic hyperglycinemia. J Pediatr 1993;122:325.
8. Zammarchi E, Donati MA, Ciani F, Pasquini E, Pela I, Fiorini P. Failure of early dextromethorphan and sodium benzoate therapy in an infant with nonketotic hyperglycinemia. Neuropediatrics 1994; 25:274-6.
9. Alemzadeh R, Gammeltoft K, Matteson K. Efficacy of low-dose dextromethorphan in the treatment of nonketotic hyperglycinemia. Pediatrics 1996;97:924-6.
10. Matalon R, Naidu S, Hughes JR, Michals K. Nonketotic hyperglycinemia: treatment with diazepam-a competitor for glycine receptors. Pediatrics 1983;71:581-4.
11. Van Hove JLK, Kishnani P, Muenzer J, et al. Benzoate therapy and canritine deficiency in non-ketotie hyperglycinemia. Am J Med Genet 199559:444-53.
12. Ohya Y, Ochi N, Mizutani N, Hayakawa C, Watanabe K. Nonketotic hyperglycinemia: treatment with NMDA antagonist and consideration of neuropathogenesis. Pediatr Neurol 1991;7:65-8.
13. Jacken J, Corbecl L, Casaer P, Carchon H, Eggermont E, Eeckels R. Dipropylacetate (valproate) and glycine metabolism. Lancet 1977;ii:617.
14. Jentsch JD, Redmond DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-lerm administration of phencyclidine. Science 1997;277-953-5.
15. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244:1360-2.
16. Tegtmeyer-Metzdorf H, Roth B, Gunther M. et al. Ketamine and strychnine treatment of an infant with nonketotic hyperglycinaemia. Eur J Pediatr 1995;154:649-53.
17. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA neurotoxicity: mechanism and prevention. Science 1991;254:1515-8.
18. Boneh A, Degani Y, Harari M. Prognostic clues and outcome of early treatment of nonkctotic hyperglycinemia. Pediair Neurol 1996;15:137-41.
19. Inoue F, Matsuo S, Yoshioka H, et al. Tryptophan therapy for nonketotic hyperglycinemia. J Inherit Metab Dis 1992;15:399-401.
20. Matsuo S, Inoue F, Takeuchi Y, Yoshioka H, Kinugasa A, Sawada T. Efficacy of tryptophan for the treatment of nonketotic hyperglycinemia: a new therapeutic approach for modulating the N-methyl-D-aspartate receptor. Pediatrics 1995;95:142-6.